Diabetes

The rising interest in GLP‑1 MASLD MASH treatment has transformed how clinicians view metabolic therapies for patients with type 2 diabetes and obesity. While GLP‑1 receptor agonists have long been recognized for their glucose-lowering and weight-loss effects, they now offer potential for improving liver outcomes, especially in individuals with metabolic …

With diabetes technology evolving rapidly, clinicians face more choices than ever before. From continuous glucose monitors (CGMs) to insulin pumps and patch devices, today’s tools can transform diabetes care—but only when matched to the right patient. This article provides a comprehensive diabetes technology comparison, helping you understand each option’s features, …

GLP‑1 receptor agonists have changed the way we treat type 2 diabetes and obesity, offering powerful glucose-lowering effects and sustained weight loss. But as more patients stay on these medications for years—not just months—questions around GLP‑1 long‑term safety have become essential to address. From gastrointestinal discomfort to gallbladder risks and …

Imagine reducing your patients’ insulin injections from 365 a year to just 52. That’s the promise of once‑weekly insulin — a next-generation option designed to simplify treatment, enhance adherence, and improve patient outcomes. While this innovation is gaining traction, many healthcare providers still have questions about when and how to …

Early research suggests GLP‑1 drugs may reduce alcohol intake by dampening reward signaling and hedonic hunger, sparking interest among diabetes clinicians about the potential of GLP-1 alcohol use reduction. While findings so far are promising, understanding the nuances of the evidence is essential when talking with patients. This article explores …

Type 1 diabetes doesn’t have to be a surprise. Thanks to type 1 diabetes autoantibody screening, clinicians can now identify individuals at high risk before symptoms even appear. This early detection opens doors for proactive monitoring, patient education, and potentially delaying or preventing full-blown disease. But who should be screened? …

GLP‑1 receptor agonists have transformed the way we manage type 2 diabetes and obesity—but could they also play a role in sleep apnea treatment? The intersection of GLP-1 sleep apnea benefits is gaining attention, with new evidence suggesting these therapies may offer more than just weight loss. With diabetes and …

The rise of GLP-1 obesity treatment has transformed how clinicians approach patients with both obesity and diabetes. These therapies, originally developed for glucose control, now show robust benefits in weight management. However, as use becomes more common in clinical practice, endocrinologists and primary care providers must balance glycemic outcomes, weight …

As the landscape of diabetes care evolves, one question continues to surface: are we focusing too much on glucose and not enough on the bigger cardiometabolic picture? In recent years, glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) have moved from glucose-focused agents to powerful tools in cardiovascular and metabolic risk reduction. …

Hospital discharge marks a critical juncture in the care of people with diabetes. It’s a period often riddled with risk—confusion about medications, fluctuating blood sugar levels, and a lack of follow-up can easily derail recovery. As clinicians, how can we improve post-discharge outcomes and reduce readmissions? This practical checklist offers …